Emergent BioSolutions is up 7.9%, or 56c to $7.62.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EBS:
- Emergent Bio (NYSE:EBS) Soars on Approval for Anthrax Vaccine
- Emergent BioSolutions announces FDA approved CYFENDUS
- Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
- Emergent BioSolutions falls -6.3%
- Emergent BioSolutions Announces CEO Transition